| Homocysteine increases the risk associated with hyperlipidaemia. | |
| | |
MedLine Citation:
|
PMID: 19276985 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The European Concerted Action Project 'Homocysteine and Vascular Disease' showed that an elevated homocysteine is associated with a substantially increased risk of cardiovascular disease, and particularly when combined with other factors such as smoking, hypertension and hypercholesterolaemia. The purpose of this study was to examine the potential interactions between homocysteine and individual lipid subfractions. In addition, it was hypothesized that HDL cholesterol may protect against hyperhomocysteinaemia because HDL cholesterol is associated with the enzyme paroxonase, which reduces oxidization of homocysteine to the harmful metabolite, homocysteine thiolactonase. METHODS: Data from a multicentre European case-control study (750 cases and 800 controls) were used for analysis. The risks of vascular disease associated with homocysteine, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apoprotein A1 and apoprotein B were established. The effect of elevated homocysteine on the cardiovascular risk associated with each lipid subfraction was then examined. RESULTS: As expected, homocysteine, total cholesterol, LDL cholesterol, triglycerides and apolipoprotein B were associated with cardiovascular risk. HDL cholesterol was inversely related to risk. Homocysteine increased the risk associated with all lipid measures. In contrast, a low plasma cholesterol does not seem to confer protection against the risk associated with a raised plasma homocysteine. Hyperhomocysteinaemia is associated with an increased risk at all levels of HDL cholesterol, conversely, in those with elevated homocysteine HDL cholesterol levels result in reduced risk. CONCLUSION: In general, the increased cardiovascular risk associated with elevated homocysteine is evident across the spectrum cholesterol subfraction levels. |
| | |
Authors:
|
Caroline Daly; Anthony P Fitzgerald; Patrick O'Callaghan; Patrick Collins; Marie Therese Cooney; Ian M Graham; |
Related Documents
:
|
14561435 - Serum cholesterol and impulsivity in a large sample of healthy young men. 7418145 - Plasma high-density lipoprotein cholesterol: association with measurements of body mass... 11948055 - Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated ballo... 11999145 - Beyond ldl-c--the importance of raising hdl-c. 16597425 - Long term effect of post-weaning rhythm on the body fat and performance of rabbit doe. 6696105 - Role of dietary preferences in the weaning pattern of the rat. |
Publication Detail:
|
Type: Journal Article; Multicenter Study |
Journal Detail:
|
Title: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology Volume: 16 ISSN: 1741-8275 ISO Abbreviation: Eur J Cardiovasc Prev Rehabil Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-16 Completed Date: 2009-06-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101192000 Medline TA: Eur J Cardiovasc Prev Rehabil Country: England |
Other Details:
|
Languages: eng Pagination: 150-5 Citation Subset: IM |
Affiliation:
|
Royal Brompton Hospital, Sydney St, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Apolipoprotein A-I / blood Apolipoproteins B / blood Biological Markers / blood Cardiovascular Diseases / etiology* Case-Control Studies Cholesterol, HDL / blood Cholesterol, LDL / blood Europe Female Homocysteine / blood* Humans Hyperhomocysteinemia / blood, complications* Hyperlipidemias / blood, complications* Lipids / blood* Logistic Models Male Middle Aged Odds Ratio Pilot Projects Risk Assessment Risk Factors Triglycerides / blood Up-Regulation |
| Chemical | |
Reg. No./Substance:
|
0/APOA1 protein, human; 0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipids; 0/Triglycerides; 454-28-4/Homocysteine |
| Investigator | |
Investigator/Affiliation:
|
Lars Brattstrom / ; Helga Refsum / ; Per M Ueland / ; Roberto J Palma-Reis / ; Armando C Sales Luis / ; Richard G Sheahan / ; Bo Israelsson / ; Cuno Uiterwaal / ; Jacqueline C Witteman / ; Dorothy McMaster / ; Alun Evans / ; Paolo Rubba / ; Generoso Andria / ; Helene Bellet / ; Jan C Wautrecht / ; Harold W de Valk / ; Francoise M Parrot-Roulaud / ; Kok Soon Tan / ; Isabella Higgins / ; Danielle Garćçon / ; Maria Jose Medrano / ; Mirande Candito / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physical activity and mortality in men and women with diagnosed cardiovascular disease.
Next Document: Effects of levosimendan on the energy balance: preclinical and clinical evidence.